ResearcherFirst Affiliated Hospital of Xinjiang Medical UniversityActive in the last 2 years

Mengsi Yu

ORCID-verified (high confidence)As of 10 November 2026

Matched on ORCID iD 0000-0001-7715-3222; OpenAlex author ID A5101035676.

Their work

Papers: 3 (first author 3, last author 0)
Trials: 0
Grants: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

Serum sphingosine-1-phosphate receptor 3 serves as a biomarker for identifying PDAC. First author DOI 10.1016/j.tice.2026.103730 ↗
SPHK1 Promotes Pancreatic Cancer Lymphangiogenesis Through the Activation of ERK in LECs. First author DOI 10.1007/s12033-024-01192-9 ↗
Increased SPHK1 and HAS2 Expressions Correlate to Poor Prognosis in Pancreatic Cancer. First author DOI 10.1155/2021/8861766 ↗

Closest collaborators

The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Zhaoyun Chen · 2 shared papers, 2021–2026
- Paper Serum sphingosine-1-phosphate receptor 3 serves as a biomarker for identifying PDAC. DOI 10.1016/j.tice.2026.103730 ↗
- Paper Increased SPHK1 and HAS2 Expressions Correlate to Poor Prognosis in Pancreatic Cancer. DOI 10.1155/2021/8861766 ↗
Hui Li · 1 shared paper, 2025
- Paper SPHK1 Promotes Pancreatic Cancer Lymphangiogenesis Through the Activation of ERK in LECs. DOI 10.1007/s12033-024-01192-9 ↗
Zhaoxia Zhang · 1 shared paper, 2021
- Paper Increased SPHK1 and HAS2 Expressions Correlate to Poor Prognosis in Pancreatic Cancer. DOI 10.1155/2021/8861766 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.